Table 1.
Clinical characteristics of patients with IgA nephropathy
| Characteristics | Value |
|---|---|
| Age (yr), mean±SD (median, IQR) | 33.9±11.9 (32, 25–41) |
| Men, n (%) | 361 (51.4) |
| Serum creatinine (mg/dl), mean±SD (median, IQR) | 1.15±0.54 (1.01, 0.81–1.29) |
| eGFR (ml/min per 1.73 m2), mean±SD (median, IQR) | 84.0±29.1 (86.5, 62.3–105.3) |
| CKD stage 1, n (%)a | 326 (46.4) |
| CKD stage 2, n (%)a | 222 (31.6) |
| CKD stage 3a, n (%)a | 77 (11.0) |
| CKD stage 3b, n (%)a | 46 (6.4) |
| CKD stage 4, n (%)a | 32 (4.6) |
| Baseline proteinuria (g/d), mean±SD (median, IQR) | 2.49±2.65 (1.60, 0.87–3.09) |
| SBP (mmHg), mean±SD (median, IQR) | 124±15 (123, 115–130) |
| DBP (mmHg), mean±SD (median, IQR) | 79±12 (80, 70–85) |
| Baseline MAP (mmHg), mean±SD (median, IQR) | 93.8±12.2 (93.3, 85.0–100.0) |
| Haas classification, n (%) | |
| I | 65 (9.2) |
| II | 9 (1.3) |
| III | 309 (44) |
| IV | 242 (34.4) |
| V | 78 (11.1) |
| Follow-up (mo), mean±SD (median, IQR) | 45.0±28.8 (38, 23–59) |
| Proteinuria at month 6 (g/d), mean±SD (median, IQR) | 1.08±1.04 (0.73, 0.32–1.36) |
| SBP at month 6 (mmHg) , mean±SD (median, IQR) | 118±15 (120, 110–125) |
| TA proteinuria (g/d), mean±SD (median, IQR) | 1.12±1.05 (0.80, 0.44–1.47) |
| TA MAP (mmHg), mean±SD (median, IQR) | 90.0±8.7 (89.4, 83.8–95.6) |
| Slope eGFR (ml/min per 1.73 m2 per yr), mean±SD (median, IQR) | −3.12±8.0 (−2.41, −6.34–0.17) |
| Treatment, n (%) | |
| RAS inhibition therapy | 676 (96.2) |
| Glucocorticoids or other immunosuppressive agents | 316 (45.0) |
| Untreated | 14 (1.99) |
| ESKD | 62 (8.8) |
| eGFR decreased >50% or ESKD | 91 (12.9) |
| Death | 7 (0.99) |
IQR, interquartile range; SBP, systolic BP; DBP, diastolic BP; MAP, mean arterial pressure; TA proteinuria, time-averaged proteinuria; TA MAP, time-averaged MAP; RAS, renin-angiotensin system; ESKD, end stage kidney disease.
a
CKD stages 1, 2, 3a, 3b, and 4 were divided by eGFR≥90, 60–89, 45–59, 30–44, and 15–29 ml/min per 1.73 m2, respectively.